Fulgent Genetics Inc FLGT.OQ FLGT.O is expected to show a rise in quarterly revenue when it reports results on May 2 for the period ending March 31 2025
The El Monte California-based company is expected to report a 10.5% increase in revenue to $71.257 million from $64.49 million a year ago, according to the mean estimate from 3 analysts, based on LSEG data.
LSEG's mean analyst estimate for Fulgent Genetics Inc is for a loss of 18 cents per share.
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Fulgent Genetics Inc is $20.00, above its last closing price of $18.13.
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Dec. 31 2024 | -0.12 | -0.12 | 0.04 | Beat | 132.4 |
Sep. 30 2024 | -0.15 | -0.15 | 0.31 | Beat | 302.2 |
Jun. 30 2024 | -0.30 | -0.30 | 0.15 | Beat | 150 |
Mar. 31 2024 | -0.32 | -0.32 | -0.01 | Beat | 96.9 |
Dec. 31 2023 | -0.28 | -0.29 | 0.28 | Beat | 197.7 |
Sep. 30 2023 | -0.35 | -0.33 | -0.39 | Missed | -18.2 |
Jun. 30 2023 | -0.33 | -0.33 | -0.08 | Beat | 75.6 |
Mar. 31 2023 | -0.43 | -0.43 | -0.22 | Beat | 48.4 |
This summary was machine generated April 30 at 12:36 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。